Overall AKAN gets a fundamental rating of 1 out of 10. We evaluated AKAN against 191 industry peers in the Pharmaceuticals industry. AKAN has a bad profitability rating. Also its financial health evaluation is rather negative. AKAN does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year AKAN has reported negative net income.
AKAN had a negative operating cash flow in the past year.
In the past 5 years AKAN always reported negative net income.
AKAN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of AKAN (-51.76%) is worse than 63.35% of its industry peers.
The Return On Equity of AKAN (-95.78%) is worse than 62.30% of its industry peers.

		Industry Rank	Sector Rank
ROA	-51.76%
ROE	-95.78%
ROIC	N/A

ROA(3y)-148.92%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 24.91%, AKAN is in line with its industry, outperforming 54.45% of the companies in the same industry.
AKAN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	24.91%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AKAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKAN has more shares outstanding
Compared to 1 year ago, AKAN has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -11.52, we must say that AKAN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.52, AKAN is not doing good in the industry: 74.87% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.08 indicates that AKAN is not too dependend on debt financing.
The Debt to Equity ratio of AKAN (0.08) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-11.52

ROIC/WACCN/A

WACC7.43%

2.3 Liquidity

AKAN has a Current Ratio of 1.39. This is a normal value and indicates that AKAN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of AKAN (1.39) is worse than 72.77% of its industry peers.
AKAN has a Quick Ratio of 1.39. This is a normal value and indicates that AKAN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.39, AKAN is doing worse than 65.97% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.39
Quick Ratio	1.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AKAN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.31%, which is quite impressive.
AKAN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -61.27%.
AKAN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 172.39% yearly.

EPS 1Y (TTM)99.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.31%

Revenue 1Y (TTM)-61.27%

Revenue growth 3Y172.39%

Revenue growth 5YN/A

Sales Q2Q%97.47%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.